Auris Medical - Model AM-201 - Betahistine Spray for Antipsychotic-Induced Weight Gain - Brochure

Auris Medical is developing AM-201, an intranasal formulation of betahistine, for the treatment or prevention of antipsychotic-induced weight gain and drowsiness / somnolence. Weight gain and associated metabolic problems such as impaired glucose tolerance and new-onset diabetes, hyperlipidemia, and cardiovascular disease and drowsiness are major side effects of drugs for schizophrenia and/or bipolar disorder. Oral betahistine is approved for the treatment of vertigo and Meniere’s disease in about 115 countries worldwide, but not in the United States.